Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center

Thoracic Cancer

Volumn 7, Issue 4, 2016, Pages 399-405

  Zhu, Yixiang ^a   Zhai, Xiaoyu ^a   Chen, Sipeng ^b   Wang, Ziping ^a  

^a CANCER HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy (ACT); non small cell lung cancer (NSCLC); optimal time for ACT

Indexed keywords

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SURVIVAL RATE; TIME TO TREATMENT; TREATMENT DURATION;

EID: 84990208948     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12342     Document Type: Article

References (25)

1. Douillard JY, Rafael R, Mario DL et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006; 7: 719–727.
2. Lin ZZ, Shau WY, Shao YY et al. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study. Oncologist 2012; 17: 1294–1302.
3. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–2597.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste, J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–360.
5. Strauss GM, Herndon JE, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043–5051.
6. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA 2011; 305: 2335–2342.
7. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010; 46: 1049–1055.
8. Lima ISF, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer 2011; 117: 3833–3840.
9. Hershman DL, Wang X, McBride R et al. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 2006; 99: 313–321.
10. American Thoracic Society. Medical section of the American Lung Association. Clinical staging of primary lung cancer. Am Rev Respir Dis 1983; 127: 659–664.
11. Oken MM, Creech, RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
12. Park SY, Lee, JG, Kim J et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg 2013; 8: 151.
13. Tsutani Y, Miyata Y, Kushitani K, Takeshima Y, Yoshimura M, Okada M. Propensity score–matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2014; 148: 1179–1185.
14. Bordoni R. Consensus conference: Multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 2008; 13: 945–953.
15. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009; 6: 194–200.
16. Saisho S, Yasuda K, Maeda A et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiov Th 2013; 16: 166–172.
17. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552–3559.
18. Ramsden K, Laskin J, Ho C. Adjuvant chemotherapy in resected stage II non-small cell lung cancer: Evaluating the impact of dose intensity and time to treatment. Clin Oncol 2015; 27: 394–400.
19. Booth CM, Shepherd FA, Peng Y et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: A population-based study. Cancer 2013; 119: 1243–1250.
20. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: Present and future. Lung Cancer 2008; 60 (Suppl 2): S23–30.
21. Mikes RE, Jordan F, Hutarew G, Studnicka M. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer 2015; 90: 614–616.
22. Casaluce F, Sgambato A, Maione P et al. ALK inhibitors: A new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013; 8: 55–67.
23. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). (Published erratum appears in J Clin Oncol 2004; 22: 4863) J Clin Oncol 2003; 21: 2237–2246.
24. Yoshida T, Yoh K, Niho S et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer 2015; 90: 477–483.
25. Shen W, Jian J, Zuo Y et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial. Radiother Oncol 2014; 110: 120–125.